PROVENGE (Sipuleucel-T) in Prostate Cancer: The First FDA-Approved Therapeutic Cancer Vaccine

@article{Cheever2011PROVENGEI,
  title={PROVENGE (Sipuleucel-T) in Prostate Cancer: The First FDA-Approved Therapeutic Cancer Vaccine},
  author={Martin A. Cheever and Celestia S. Higano},
  journal={Clinical Cancer Research},
  year={2011},
  volume={17},
  pages={3520 - 3526}
}
Sipuleucel-T (PROVENGE; Dendreon) is the first therapeutic cancer vaccine to be approved by the U.S. Food and Drug Administration. In men who have metastatic castration-resistant prostate cancer with no or minimal symptoms, sipuleucel-T prolongs median survival by 4.1 months compared with results in those treated with placebo. At 3 years, the proportion of patients in the vaccine group who were alive was 50% higher than that in the control group (31.7% versus 21.7%, respectively). Sipuleucel-T… 

Figures and Tables from this paper

Sipuleucel-T and Androgen Receptor-Directed Therapy for Castration-Resistant Prostate Cancer: A Meta-Analysis
TLDR
Treatment with sipuleucel-T and AR-directed therapies significantly improved overall survival in patients with CRPC and improved time-to-progression and reduction of PSA level ≥50%.
IL-7 expands lymphocyte populations and enhances immune responses to sipuleucel-T in patients with metastatic castration-resistant prostate cancer (mCRPC)
TLDR
The use of rhIL-7 after sip-T in patients with mCRPC led to a significant expansion of CD4+ and CD8+ T cells, and CD56bright natural killer cells compared with observation after treatment, and improved antigen-specific humoral and T cell proliferative responses over time.
p53MVA Therapy in Patients with Refractory Gastrointestinal Malignancies Elevates p53-Specific CD8+ T-cell Responses
TLDR
Combination of p53MVA with immune checkpoint inhibition could help sustain immune responses and lead to enhanced clinical benefit in patients with refractory gastrointestinal cancers.
Phase I clinical trial of multiple-peptide vaccination for patients with advanced biliary tract cancer
TLDR
Multiple-peptide vaccination was well tolerated and induced peptide-specific T-cell responses in patients with advanced biliary tract cancer and appeared to be prognostic of OS.
Efficacy of Adoptive Immune-cell Therapy in Patients with Advanced Gastric Cancer: A Retrospective Study.
TLDR
Investigation of the efficacy of immune-cell therapy, using in vitro-activated T-lymphocytes with and without dendritic cells, in combination with standard therapies in terms of the survival of patients with advanced GC revealed that performance status, the type of immunity, and prior treatment were independent prognostic factors for patients with GC.
Use of immunotherapy in the treatment of gastric cancer
TLDR
The current review presents a summary of the clinical effects of checkpoint inhibitors, including CAR-T and tumor vaccines, in the treatment of GC.
A phase I clinical study of immunotherapy for advanced colorectal cancers using carcinoembryonic antigen-pulsed dendritic cells mixed with tetanus toxoid and subsequent IL-2 treatment
TLDR
The results of this study indicate that it is feasible and safe to treat colorectal cancer patients using this protocol, and an increase in the anti-CEA immune response and a clinical benefit was observed in a small fraction of patients.
Therapeutic cancer vaccines and combination immunotherapies involving vaccination
TLDR
This review discusses the current status of the clinical evaluation of different classes of therapeutic cancer vaccines and possible avenues for future development, focusing on enhancing the magnitude and quality of cancer-specific immunity by either the functional reprogramming of patients’ endogenous dendritic cells or the use of ex vivo-manipulated dendedritic cells as autologous cellular transplants.
Sipuleucel-T for the treatment of advanced prostate cancer.
TLDR
The clinical development program and key efficacy, safety, and immune response findings from the phase III studies are presented and the integration of sipuleucel-T into the treatment paradigm of advanced prostate cancer is discussed.
Immunological responses to a multi-peptide vaccine targeting cancer-testis antigens and VEGFRs in advanced pancreatic cancer patients
TLDR
The elicitation of multiple and robust peptide-specific T-cell responses as well as the status of host lymphocytes may be useful prognostic factors among patients with advanced pancreatic cancer treated with peptides-based anticancer vaccines.
...
...

References

SHOWING 1-10 OF 48 REFERENCES
Sipuleucel-T immunotherapy for castration-resistant prostate cancer.
TLDR
The use of sipuleucel-T prolonged overall survival among men with metastatic castration-resistant prostate cancer and immune responses to the immunizing antigen were observed in patients who received sipuleUcel- T.
Abstract 5608: Sipuleucel-T treatment results in sequentialex vivoactivation of APCs and T cells during the culture step - evidence forin vivoimmunological priming
TLDR
These data provide strong evidence that sipuleucel-T activates APCs ex vivo and facilitates in vivo and ex vivo priming of T cells, and demonstrate evidence of increased APC and T cell activation markers as well as production of T cellactivation-associated cytokines.
Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells.
  • E. Small, P. Fratesi, F. Valone
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2000
TLDR
Provenge is a novel immunotherapy agent that is safe and breaks tolerance to the tissue antigen PAP and preliminary evidence for clinical efficacy warrants further exploration.
Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate.
  • A. Reid, G. Attard, J. D. de Bono
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2010
TLDR
Abiraterone acetate has significant antitumor activity in post-docetaxel patients with castration-resistant prostate cancer (CRPC), and Randomized, phase III trials of abirater one acetate are underway to define the future role of this agent.
Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer.
  • P. Kantoff, T. Schuetz, W. Godfrey
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2010
TLDR
PROSTVAC-VF immunotherapy was well tolerated and associated with a 44% reduction in the death rate and an 8.5-month improvement in median OS in men with mCRPC, providing preliminary evidence of clinically meaningful benefit but need to be confirmed in a larger phase III study.
Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer.
  • D. Danila, M. Morris, H. Scher
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2010
TLDR
This trial evaluated the efficacy and safety of AA in combination with prednisone to reduce the symptoms of secondary hyperaldosteronism that can occur with AA monotherapy, with encouraging antitumor activity in heavily pretreated CRPC patients.
Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer.
  • P. Burch, J. Breen, S. Vuk-Pavlović
  • Biology, Medicine
    Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2000
TLDR
Dendritic cells exposed to antigen ex vivo can induce antigen-specific cellular immunity in prostate cancer patients, warranting further studies of this mode of immunotherapy.
Twelve immunotherapy drugs that could cure cancers.
  • M. Cheever
  • Biology, Medicine
    Immunological reviews
  • 2008
TLDR
A well-vetted ranked list of agents with high potential to serve as immunotherapeutic drugs, all with proven ability to augment T-cell responses, and how these agents are overwhelmingly likely to have an impact in combinations dictated by biology.
Technology evaluation: APC-8015, Dendreon.
  • B. Rini
  • Medicine, Biology
    Current opinion in molecular therapeutics
  • 2002
Dendreon (formerly Activated Cell Therapy), in association with the Mayo Clinic, is developing the dendritic cell therapy APC-8015 (Provenge) for the potential treatment of hormone-refractory
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.
TLDR
The improvement in median survival of nearly two months with docetaxel and estramustine, as compared with mitoxantrone and prednisone, provides support for this approach in men with metastatic, androgen-independent prostate cancer.
...
...